Commit To Purchase Prothena Corp At $17.50, Earn 33.1% Annualized Using Options
at The Street - Fri Dec 12, 10:45AM CST
Investors considering a purchase of Prothena Corp plc shares, but tentative about paying the going market price of $17.97/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
PRTA: 18.15 (-0.34)
First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST
IPXL: 31.16 (-0.74), ADMS: 13.97 (-0.42), TEVA: 55.92 (-0.92), ACOR: 38.70 (+0.06), PRTA: 18.15 (-0.34), NDRM: 7.19 (-0.17)
Prothena to Present at the Oppenheimer 25th Annual Healthcare Conference in New York
GlobeNewswire - Mon Dec 08, 4:11PM CST
Prothena Corporation plc (Nasdaq
PRTA: 18.15 (-0.34)
Prothena Corporation (PRTA) Falls: Stock Goes Down 5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 7:37AM CST
Shares of Prothena Corporation (PRTA) fell over 5% on the day. This continues the most recent downtrend for PRTA, as the stock is down over 9% since Nov 28. Although this slump was obviously disappointing the company has seen positive revisions and its current year loss consensus has narrowed over the past few weeks.
BIIB: 344.49 (+2.16), ANIP: 54.28 (+2.33), PRTA: 18.15 (-0.34), AFFX: 8.94 (-0.36)
Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis
Thomson Reuters ONE - Tue Dec 02, 3:05PM CST
- New and Updated Results Show 50% Response Rate in 14 Cardiac-Evaluable Patients
PRTA: 18.15 (-0.34)
Why You Shouldn't Bet Against Prothena Corporation (PRTA) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 7:43AM CST
Prothena Corporation might be an intriguing choice for investors as it is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective
PRTA: 18.15 (-0.34)
Prothena's Management Presents at 2014 Credit Suisse Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Tue Nov 11, 2:16PM CST
PRTA: 18.15 (-0.34)
Prothena Reports Third Quarter 2014 Financial Results and R&D Progress
GlobeNewswire - Mon Nov 03, 5:29PM CST
-- Net cash used in operating activities was $12.3 million in the third quarter, while quarter-end cash position of $306.2 million provides solid runway for advancement of multiple programs
PRTA: 18.15 (-0.34)
Prothena beats by $0.12, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 4:06PM CST
PRTA: 18.15 (-0.34)
Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT
BIIB: 344.49 (+2.16), MNOV: 3.60 (+0.18), CHTP: 6.52 (-0.03), ADMS: 13.97 (-0.42), ACOR: 38.70 (+0.06), BCLI: 2.90 (-0.06), BSX: 13.00 (+0.11), IPXL: 31.16 (-0.74), AVNR: 16.95 (-0.02), ACAD: 32.53 (-0.10), CVTS: (), MRK: 57.72 (-1.62), TEVA: 55.92 (-0.92), PRTA: 18.15 (-0.34), PRAN: 1.86 (-0.05), FOLD: 8.15 (+0.18), CUR: 2.58 (-0.09)
The Next Biotech Buyout Stock
Motley Fool Staff - Motley Fool - Fri Oct 10, 7:15AM CDT
Biotech stocks are notoriously volatile, making them best suited for only the most risk-tolerant investors. But for those willing to take the risk, biotech companies can often make a big splash; particularly when a bigger fish gobbles them up....
JNJ: 104.43 (-2.29), PTLA: 28.27 (-0.27), PFE: 30.95 (-0.70), BMY: 58.75 (-0.93), PRTA: 18.15 (-0.34), PBYI: 196.34 (-7.66)
Why Prothena Corporation (PRTA) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 7:43AM CDT
Prothena Corporation belongs to the Medical and Biomedical industry, is a decent pick as it witnessed solid earnings estimate revision activity with a favorable Zacks Industry Rank.
PRTA: 18.15 (-0.34)
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
KMX: 58.30 (-1.21), CRUS: 18.84 (-0.12), MEI: 34.66 (-0.99), PRTA: 18.15 (-0.34), GPX: 31.40 (-0.18)
Prothena Announces Presentation at Federation of European Physiological Societies 2014 Congress
GlobeNewswire - Tue Aug 26, 3:08PM CDT
-- Data to be Presented by Dr. Timo Siepmann on the Discovery of a Potential New Non-Invasive Biomarker for Parkinson's Disease
PRTA: 18.15 (-0.34)
Dr. Dale Schenk to Discuss Parkinson's Disease at 2014 Rejuvenation Biotechnology Conference
Thomson Reuters ONE - Mon Aug 18, 3:05PM CDT
DUBLIN, Ireland, Aug. 18, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
PRTA: 18.15 (-0.34)